At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Not Yet Opened 08-19 16:00:00 EDT
493.49
+53.65
+12.20%
High494.06Low448.46Vol22.71M
Open449.61D1 Closing439.83Amplitude10.37%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O421.54MT/O Rate--Tradable Shares0.00
P/B2.699389ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Editas Medicine Initiated at Buy by Ladenburg Thalmann
Dow Jones  ·  08-18 20:58
Editas Medicine Initiated at Buy by Ladenburg Thalmann
Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-10
Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement
Reuters  ·  08-08
Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement
Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees
Reuters  ·  08-08
Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-08
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)
TIPRANKS  ·  08-07
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)
Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview
Reuters  ·  08-07
Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)
TIPRANKS  ·  08-07
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)
CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration
Reuters  ·  08-07
CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration
Oculis Q2 Net Loss Narrows Despite Higher Expenses
Reuters  ·  08-07
Oculis Q2 Net Loss Narrows Despite Higher Expenses
Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit
Reuters  ·  08-07
Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit
Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06
Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary
Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens
Reuters  ·  08-06
Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens
Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million
Reuters  ·  08-06
Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million
Intellia Therapeutics Q2 Net Income USD -106.634 Million
Reuters  ·  08-06
Intellia Therapeutics Q2 Net Income USD -106.634 Million
Intellia Therapeutics Q2 Basic EPS USD -0.8
THOMSON REUTERS  ·  08-06
Intellia Therapeutics Q2 Basic EPS USD -0.8
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)
TIPRANKS  ·  08-06
Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)
TIPRANKS  ·  08-06
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)
Editas Medicine Strengthens Board With New Cardiology Director
TIPRANKS  ·  08-06
Editas Medicine Strengthens Board With New Cardiology Director
Editas Medicine Q2 Net Loss Narrows and Beats Estimates
Reuters  ·  08-06
Editas Medicine Q2 Net Loss Narrows and Beats Estimates

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--